Vbi Vaccines Stock News

VBI Vaccines Inc. (NASDAQ:VBIV)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $3.12, but opened at $2.89. VBI Vaccines shares last traded at $2.81, with a volume of 44,604 shares changing hands. Separately, Zacks Investment Research cut shares of VBI Vaccines from a “buy” rating to a […]

VBI Vaccines Inc (NASDAQ: VBIV ) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company''s recurrent glioblastoma (GBM) vaccine VBI-1901 + granulocyte-macrophage colony-stimulating factor (GM-CSF) arm showed 18-month OS of 30% (n=3/10) One patient is still on protocol past week 86, with a 93% tumor reduction relative to initiation of Full story available on Benzinga.com

VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's recurrent glioblastoma (GBM) vaccine VBI-19

VBI Vaccines just got the green light from the FDA for its new Hepatitis B vaccine. VBIV stock is reacting well so far today.

VBI Vaccines just got the green light from the FDA for its new Hepatitis B vaccine. VBIV stock is reacting well so far today.

The stock price of VBI Vaccines Inc. (Nasdaq: VBIV) increased by over 19% pre-market today. This is why it happened.

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week. Shares of companies with a COVID portfolio, including a vaccine, a treatment or both, reacted with strong moves to the upside in the truncated session on Friday. Takeda Pharmaceutical Company Limited (NYSE: TAK ) and Aadi Bioscience, Inc. (NASDAQ: AADI ) received Food and Drug Administration nod for their Livtencity and Fyarro, respectively. Here are the catalysts that could impact trading in the upcoming week: Conferences The Evercore ISI 4th Annual HealthCONx Virtual Conference: Nov. 30-Dec. 2 Piper Sandler 33rd Annual Virtual Healthcare Conference: Nov. 29-Dec. 2 American Epilepsy Society, or AES, 2021 Annual Meeting: Dec. 3-7, in Full story available on Benzinga.com

Zacks Investment Research downgraded shares of VBI Vaccines (NASDAQ:VBIV) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The companys eVLP vaccine platform allows for the design []

VBI Vaccines Inc. (NASDAQ:VBIV) Analysts at Jefferies Financial Group increased their FY2021 EPS estimates for shares of VBI Vaccines in a report issued on Thursday, November 18th. Jefferies Financial Group analyst K. Chikere now anticipates that the biopharmaceutical company will post earnings of ($0.27) per share for the year, up from their previous estimate []

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 25.00% and -58.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US. Approval in the US - and Europe, where a marketing aut

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ